For instance, researchers found that the Gefitinib plus Vorinostat has a synergistic effect in inhibiting the growth of head and neck cancer (HNC) cells.[46] In addition, the efficacy of this combination is independent on the HPV status, a strong prognosis biomarker in HNC cancer.[46] Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) while Vorinostat is a Histone deacetylase inhibitor (HDACi). The gene discussed is EGFR; the disease is head and neck cancer.